Acurx Pharmaceuticals, Inc. Stock-Based Compensation
Acurx Pharmaceuticals, Inc. (ACXP) reported Stock-Based Compensation of $458.82 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-13
- Acurx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $200.54K, a 38.15% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $258.29K, a 22.58% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $294.79K, a 14.60% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $294.79K, a 14.60% decline year-over-year.
- Acurx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $1.25M, a 52.06% decline from fiscal 2024.
- Acurx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $2.60M, a 18.86% decline from fiscal 2023.
- Acurx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $3.21M, a 11.66% increase from fiscal 2022.
- Acurx Pharmaceuticals, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $2.87M, a 44.29% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $200.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $458.82K 10-Q · filed 2026-08-13 | $753.62K derived: sum of 3 quarters · filed 2026-08-13 | $1.05M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $258.29K 10-Q · filed 2026-05-11 | $553.08K derived: sum of 2 quarters · filed 2026-05-11 | $847.87K derived: sum of 3 quarters · filed 2026-05-11 | $1.17M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $294.79K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $589.59K derived: sum of 2 quarters · filed 2026-03-12 | $913.80K derived: sum of 3 quarters · filed 2026-08-13 | $1.25M 10-K · filed 2026-03-12 |
| 2025-09-30 | $294.79K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $619.01K derived: sum of 2 quarters · filed 2026-08-13 | $952.61K 10-Q · filed 2025-11-12 | $1.30M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $324.22K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $657.81K 10-Q · filed 2026-08-13 | $1.00M derived: sum of 3 quarters · filed 2026-08-13 | $1.35M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $333.60K 10-Q · filed 2026-05-11 | $678.79K derived: sum of 2 quarters · filed 2026-05-11 | $1.02M derived: sum of 3 quarters · filed 2026-05-11 | $2.04M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $345.19K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $690.38K derived: sum of 2 quarters · filed 2026-03-12 | $1.71M derived: sum of 3 quarters · filed 2026-03-12 | $2.60M 10-K · filed 2026-03-12 |
| 2024-09-30 | $345.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $1.36M derived: sum of 2 quarters · filed 2025-11-12 | $2.26M 10-Q · filed 2025-11-12 | $3.09M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.91M 10-Q · filed 2025-08-11 | $2.74M derived: sum of 3 quarters · filed 2025-08-11 | $3.58M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $894.52K 10-Q · filed 2025-05-12 | $1.73M derived: sum of 2 quarters · filed 2025-05-12 | $2.56M derived: sum of 3 quarters · filed 2025-05-12 | $3.37M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $833.28K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $1.67M derived: sum of 2 quarters · filed 2025-03-17 | $2.47M derived: sum of 3 quarters · filed 2025-03-17 | $3.21M 10-K · filed 2025-03-17 |
| 2023-09-30 | $833.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.64M derived: sum of 2 quarters · filed 2024-11-12 | $2.37M 10-Q · filed 2024-11-12 | $3.07M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $806.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $1.54M 10-Q · filed 2024-08-08 | $2.24M derived: sum of 3 quarters · filed 2024-08-08 | $2.93M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $733.47K 10-Q · filed 2024-05-14 | $1.43M derived: sum of 2 quarters · filed 2024-05-14 | $2.13M derived: sum of 3 quarters · filed 2024-05-14 | $2.84M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $696.97K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $1.39M derived: sum of 2 quarters · filed 2024-03-15 | $2.11M derived: sum of 3 quarters · filed 2024-03-15 | $2.87M 10-K · filed 2024-03-15 |
| 2022-09-30 | $696.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $1.41M derived: sum of 2 quarters · filed 2023-11-13 | $2.17M 10-Q · filed 2023-11-13 | $2.85M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $716.68K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $1.48M 10-Q · filed 2023-08-11 | $2.15M derived: sum of 3 quarters · filed 2023-08-11 | $4.22M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | $761.07K 10-Q · filed 2023-05-12 | $1.43M derived: sum of 2 quarters · filed 2023-05-12 | $3.50M derived: sum of 3 quarters · filed 2023-05-12 | $5.72M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $672.64K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $2.74M derived: sum of 2 quarters · filed 2023-03-15 | $4.96M derived: sum of 3 quarters · filed 2023-03-15 | $5.15M 10-K · filed 2023-03-15 |
| 2021-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $4.29M derived: sum of 2 quarters · filed 2022-11-10 | $4.48M 10-Q · filed 2022-11-10 | $4.67M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $2.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $2.41M 10-Q · filed 2022-08-12 | $2.60M derived: sum of 3 quarters · filed 2022-08-12 | $2.77M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | $191.67K 10-Q · filed 2022-05-10 | $379.17K derived: sum of 2 quarters · filed 2022-05-10 | $554.17K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $187.50K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-16 | $362.50K derived: sum of 2 quarters · filed 2022-03-16 | $695.83K 10-K · filed 2022-03-16 | |
| 2020-09-30 | $175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $508.33K 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | $333.33K 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B |